Pfizer's strategy and innovation head steps down Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 24 April, 2026

Discover the latest trends, challenges, and strategies shaping the future of patient experience across 80+ companies. sponsored by Courier Health

presented by This Founder Could­n't Find His Own Clin­i­cal Tri­al. Now He's En­rolling Hun­dreds of Pa­tients for Phar­ma's Biggest Names

SPOTLIGHT Live today: Is the anti-vax era at the CDC coming to an end?

news Sanofi’s tolebrutinib gets CHMP backing for certain MS patients after FDA rejection Daiichi Sankyo postpones annual results, stock dips Peer Review Pfizer’s strategy chief Andrew Baum steps down; Helus Pharma swaps out CEO after two months Substance use disorder biotech Tempero to close after earlier 'serious' safety event

Apr 28 12:30 pm ET Connection ≠ continuity: Rethinking long-term evidence in the age of tokenization sponsored by PicnicHealth Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera May 05 11:00 am ET The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development sponsored by Medable May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher May 20 11:00 am ET Application of Simple Western to analysis of antibody target affinity and specificity sponsored by Bio-Techne

US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.

in case you missed it 1. Novartis built a big business around delivering radioactive cancer treatments. Can a generic compete? 2. Updated: Regeneron snags hearing loss gene therapy approval, closes US pricing deal 3. David Reese to retire from Amgen 4. Updated: Sanofi defends Garijo appointment, says it is 'fully committed' to immunology 5. Updated: Roche says its investigational breast cancer pill could outsell Herceptin 6. News Briefing Novo's pill for kids; Altimmune’s $225M offering; Merck teams with Google Cloud